Advertisement

Reactions Weekly

, Volume 1769, Issue 1, pp 156–156 | Cite as

Daclizumab/natalizumab

Rash and infusion related reaction: 3 case reports
Case report

Reference

  1. Lockhart A, et al. Rash developing after cessation of Daclizumab for relapsing remitting MS; a case series. Multiple Sclerosis and Related Disorders 35: 239-240, Oct 2019. Available from: URL: http://doi.org/10.1016/j.msard.2019.08.008 - IrelandCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations